Genomic analysis is increasingly used for large-scale projects to understand the causes of disease. Measuring the true molecular drivers of disease and the major targets of drugs, i.e., proteins, in thousands of samples is, however, still severely limited due to high cost, poor standardization and low throughput of available methods. With nexProQ, Christoph Borchers’ lab at McGill University, MRM Proteomics Inc., and Bruker join forces to set a new benchmark for the large-scale and reliable measurement of proteins in 1000s of samples with an unprecedented liaison between highest quality and low cost. We will offer a novel and unique technology that will reduce the current cost for such measurements from ca. 1$ per protein to ¢2. Thus, nexProQ will transform health-related research projects where 1000s-10,000s of patient samples have to be analyzed in order to identify the causes and early markers of either disease or drug response. nexProQ will therefore accelerate global research in preventing and effectively treating disease. While the benefits for society and the health system will be enormous, the global biomarkers market size will reach USD B130 in 2028, with 30-40% of biomarkers being proteins, therefore representing a vast business opportunity with millions of $ in potential revenues.
Genome Centre: Génome Québec
User:
| René | Zahedi | MRM Proteomics Inc. |